26 Jul 2018 15:22
For immediate release | 26 July 2018 |
Evgen Pharma plc
("Evgen" or "the Company")
Results of AGM
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, confirms that all resolutions were duly passed at its Annual General Meeting ("AGM") held earlier today.
Enquiries:
Evgen Pharma plc Dr Stephen Franklin, CEO Richard Moulson, CFO www.evgen.com | c/o +44 (0) 20 7466 5000
| |
Buchanan Mark Court, Sophie Wills, Tilly Abraham | +44 (0) 20 7466 5000
| |
Northland Capital Partners Limited Matthew Johnson, Tom Price, Gerry Beaney (Corporate Finance) Rob Rees (Corporate Broking) | +44 (0) 20 3861 6625 | |
Notes for editors:
About Evgen Pharma plc
Evgen is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/